Gastroesophageal Junction Cancer
FDA clears application for natural killer cell therapy to treat gastrointestinal cancers
The FDA cleared an investigational new drug application for CYNK-101, a natural killer cell therapy for the treatment of patients with advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.
2-year data confirm benefit of nivolumab regimen for advanced gastric, esophageal cancers
The addition of nivolumab to chemotherapy showed durable benefit for treatment-naive patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, 2-year data from the CheckMate 649 study showed.
Sintilimab regimen extends OS in gastric, gastroesophageal junction adenocarcinoma
The addition of sintilimab to first-line chemotherapy extended OS among patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, according to topline results of a randomized phase 3 trial.
FDA grants orphan drug designation to TST001 for gastric cancer
FDA approves Opdivo for esophageal, gastroesophageal junction cancers
The FDA approved nivolumab as adjuvant treatment for certain patients with completely resected esophageal or gastroesophageal junction cancers, according to the agent’s manufacturer.
FDA approves first-line Keytruda-based regimen for advanced HER2-positive gastric cancer
The FDA granted accelerated approval to a pembrolizumab-based combination for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
FDA approves Opdivo for initial treatment of advanced gastrointestinal cancers
The FDA approved nivolumab as part of combination therapy for certain patients with gastrointestinal malignancies.
Early body weight loss linked to shorter OS in gastric, gastroesophageal junction cancer
Body weight loss may predict poor outcomes among patients with metastatic gastric or gastroesophageal junction cancer receiving third-line or later treatment, according to study results presented at Gastrointestinal Cancers Symposium.
Adding bemarituzumab to chemotherapy improves outcomes in certain gastric cancers
The addition of bemarituzumab to modified FOLFOX6 benefited patients with advanced gastric and gastroesophageal junction cancer with FGFR2b overexpression, according to data presented at Gastrointestinal Cancers Symposium.
FDA grants priority review to Keytruda-chemotherapy regimen for esophageal cancer
Pembrolizumab plus fluoropyrimidine-based chemotherapy received FDA priority review for the first-line treatment of locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer, according to a press release.